India Pharma Outlook Team | Monday, 08 September 2025
Argo Biopharmaceutical Co., a biotechnology firm in the clinical stage that specializes in the development of next-generation siRNA therapeutics, has announced the establishment of an additional strategic partnership with Novartis concerning several cardiovascular assets within Argo's pipeline.
These new agreements supplement the current collaboration between the two organizations and represent their third transaction, which includes assets from Argo's pipeline. "We are thrilled to deepen our collaboration with Novartis, a global leader in cardiovascular, renal, and metabolic areas," said Dr. Dongxu Shu, co-founder, chairman of the Board, and CEO of Argo Biopharma.
"This new collaboration further supports the innovation engine Argo has built to deliver best-in-class siRNA therapeutics while building a top-tier clinical development team across multiple geographies. Argo's ambition is to become a global biotechnology, and corporate development activities are an important component to expand the reach of our hepatic and ex-hepatic siRNA therapeutics."
Also Read: AIOCD Launches Kerala's First Pharma LLP to Boost Healthcare Access
"Long-acting siRNAs which are designed to deeply and durably target disease-causing proteins, represent an important paradigm shift in the prevention and treatment of cardiovascular diseases. We are excited to build on our work with Argo through these new agreements, which include additional molecules," said Shaun Coughlin, Global Head of Cardiovascular and Metabolism at Novartis Biomedical Research.
"Novartis is committed to advancing innovative treatments for patients with cardiovascular conditions, and our collaboration with Argo further strengthens our efforts to advance potential new therapies that address unmet medical needs."
